515 related articles for article (PubMed ID: 16846546)
1. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.
Waterbury LD; Silliman D; Jolas T
Curr Med Res Opin; 2006 Jun; 22(6):1133-40. PubMed ID: 16846546
[TBL] [Abstract][Full Text] [Related]
2. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
Bucci FA; Waterbury LD
Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
[TBL] [Abstract][Full Text] [Related]
3. Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.
Waterbury LD; Galindo D; Villanueva L; Nguyen C; Patel M; Borbridge L; Attar M; Schiffman RM; Hollander DA
J Ocul Pharmacol Ther; 2011 Apr; 27(2):173-8. PubMed ID: 21351868
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
Gerstenfeld LC; Thiede M; Seibert K; Mielke C; Phippard D; Svagr B; Cullinane D; Einhorn TA
J Orthop Res; 2003 Jul; 21(4):670-5. PubMed ID: 12798067
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
Walters T; Raizman M; Ernest P; Gayton J; Lehmann R
J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
Bucci FA; Waterbury LD
J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation.
Waterbury LD; Flach AJ
J Ocul Pharmacol Ther; 2006 Jun; 22(3):155-9. PubMed ID: 16808675
[TBL] [Abstract][Full Text] [Related]
8. Peripheral prostanoid levels and nonsteroidal anti-inflammatory drug analgesia: replicate clinical trials in a tissue injury model.
Gordon SM; Brahim JS; Rowan J; Kent A; Dionne RA
Clin Pharmacol Ther; 2002 Aug; 72(2):175-83. PubMed ID: 12189364
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
Bucci FA; Waterbury LD
Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model.
Higaki S; Watanabe K; Itahashi M; Shimomura Y
Curr Eye Res; 2009 Mar; 34(3):171-6. PubMed ID: 19274523
[TBL] [Abstract][Full Text] [Related]
11. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation.
Bucolo C; Marrazzo G; Platania CB; Romano GL; Drago F; Salomone S
J Pharm Pharmacol; 2014 Jul; 66(7):954-60. PubMed ID: 24697218
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits.
Kida T; Kozai S; Takahashi H; Isaka M; Tokushige H; Sakamoto T
PLoS One; 2014; 9(5):e96481. PubMed ID: 24796327
[TBL] [Abstract][Full Text] [Related]
13. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.
Jones J; Francis P
Expert Opin Pharmacother; 2009 Oct; 10(14):2379-85. PubMed ID: 19735215
[TBL] [Abstract][Full Text] [Related]
14. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).
Durrie DS; Kennard MG; Boghossian AJ
Adv Ther; 2007; 24(6):1278-85. PubMed ID: 18165210
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat.
Jett MF; Ramesha CS; Brown CD; Chiu S; Emmett C; Voronin T; Sun T; O'Yang C; Hunter JC; Eglen RM; Johnson RM
J Pharmacol Exp Ther; 1999 Mar; 288(3):1288-97. PubMed ID: 10027870
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal.
Brookshire HL; English RV; Nadelstein B; Weigt AK; Gift BW; Gilger BC
Vet Ophthalmol; 2015 May; 18(3):175-85. PubMed ID: 24636042
[TBL] [Abstract][Full Text] [Related]
17. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure.
Cappon GD; Cook JC; Hurtt ME
Birth Defects Res B Dev Reprod Toxicol; 2003 Feb; 68(1):47-56. PubMed ID: 12852483
[TBL] [Abstract][Full Text] [Related]
18. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
Gierse JK; Zhang Y; Hood WF; Walker MC; Trigg JS; Maziasz TJ; Koboldt CM; Muhammad JL; Zweifel BS; Masferrer JL; Isakson PC; Seibert K
J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T
Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.
Miyake-Kashima M; Takano Y; Tanaka M; Satake Y; Kawakita T; Dogru M; Asano-Kato N; Fukagawa K; Fujishima H
Jpn J Ophthalmol; 2004; 48(6):587-90. PubMed ID: 15592786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
